Related Experiment Video

Updated: Jul 8, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy

Paweł P Dimitrow1, Anetta Undas, Maria Bober

  • 12nd Department of Cardiology, Collegium Medicum, Jagiellonian University, Kopernika 17, PL 31-501 Kraków, Poland. dimitrow@mp.pl

Pharmacological Reports : PR
|January 16, 2008
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) patients exhibit elevated blood markers of endothelial dysfunction, including soluble thrombomodulin (sTM) and asymmetric dimethylarginine (ADMA). These findings suggest specific endothelial impairments in HCM, detectable through peripheral blood analysis.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Biochemistry

Background:

  • Endothelium-dependent coronary vasodilatation impairment is noted in hypertrophic cardiomyopathy (HCM).
  • Endothelial dysfunction may play a role in HCM pathophysiology.
  • Identifying blood-based biomarkers can aid in understanding HCM-related vascular changes.

Purpose of the Study:

  • To investigate circulating endothelial dysfunction markers in HCM patients.
  • To compare biomarker levels between HCM patients and healthy controls.
  • To explore differences in biomarker levels between obstructive and non-obstructive HCM.

Main Methods:

  • Plasma levels of soluble thrombomodulin (sTM), von Willebrand factor (vWF), tissue factor pathway inhibitor (TFPI), asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and the L-arginine/ADMA ratio were measured.
  • 29 HCM patients (11 with left ventricular outflow tract obstruction) were compared to 29 age- and sex-matched controls.
  • Statistical analysis was performed to compare biomarker levels between groups.

Main Results:

  • HCM patients showed significantly elevated sTM, TFPI, ADMA, and SDMA levels compared to controls.
  • The L-arginine/ADMA ratio was significantly decreased in HCM patients.
  • vWF levels did not differ significantly between HCM patients and controls.
  • Obstructive HCM subgroup had higher ADMA, SDMA, and sTM levels than the non-obstructive subgroup.

Conclusions:

  • HCM patients demonstrate distinct peripheral blood endothelial dysfunction markers, including increased sTM and TFPI.
  • Elevated ADMA and SDMA, with a reduced L-arginine/ADMA ratio, indicate impaired nitric oxide pathways in HCM.
  • These findings highlight the presence of endothelial dysfunction in HCM, potentially contributing to disease progression.

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 200007:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...